Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cangrelor Can’t Escape Its Past At FDA Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.

You may also be interested in...



Medicines Co. Gains Kengreal Approval; Can It Alter Clinical Practice Too?

Antiplatelet's indication is narrow, but TMC hopes to leverage cultural changes in 'door-to-procedure' times.

Cangrelor Survives Second Advisory Committee, But Narrowly

FDA panel members were not enthusiastic about the antiplatelet, but felt it could help ‘some people.’

Cangrelor’s Second Advisory Committee Could Be The Charm

FDA reviewers again recommended approval of the antiplatelet, but this time there doesn’t appear to be opposition from the team leader.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel